secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001641172-25-022592
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics effects 1-for-12 reverse stock split effective August 4, 2025
--------------------------------------------------------------------------------

- Reverse stock split at ratio 1-for-12 became effective on August 4, 2025.
- No fractional shares issued; rounding up to nearest whole share; authorized shares unchanged at 330M common, 1M preferred.
- Stock continues trading under symbol CLDI on NYSE American with new CUSIP 320703408.
- Company states reverse split aims to optimize market dynamics and broaden investor appeal.
- All outstanding equity awards adjusted proportionally to reflect the reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225022592/0001641172-25-022592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225022592/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer